肥胖与肾脏病:从人群到基础科学及寻找新的治疗靶点
全球肾脏病负担与肥胖和糖尿病增加平行上升,尽管广泛使用肾素-血管紧张素-醛固酮系统(RAAS)抑制剂并积极控制血压和血糖,肥胖和糖尿病患者进展至终末期肾病(ESRD)的风险仍存在。内皮功能障碍及相关的肾小管间质纤维化是驱动肥胖相关慢性肾脏病(CKD)发生和进展的关键机制。实验数据提示运动、靶向炎症和氧化应激、降低尿酸以及靶向盐皮质激素受体信号和/或钠通道抑制可能改善肾小管间质纤维化并减缓肾病进展。
要点
- 肥胖和糖尿病患者的CKD和ESRD负担沉重,尽管使用RAAS抑制剂和积极控制血压血糖,进展至ESRD的风险仍存在。
- 内皮功能障碍及相关肾小管间质纤维化是驱动肥胖相关CKD发生和进展的关键机制,但精确的交互机制尚不清楚。
- 实验数据提示运动、靶向炎症和氧化应激、降低尿酸以及靶向盐皮质激素受体信号和/或钠通道抑制可能改善肾小管间质纤维化并减缓肾病进展。
核心结论
- 肥胖相关CKD的进展机制涉及内皮功能障碍和肾小管间质纤维化,针对这些机制的新策略可能预防或阻断疾病进展。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 全球肾脏病负担与肥胖和糖尿病增加平行上升,CKD和ESRD及其合并症在美国 alone 花费医疗系统数千亿美元。
- 尽管广泛使用RAAS抑制剂并积极控制血压和血糖,肥胖和糖尿病患者进展至ESRD的风险仍存在。
- 内皮功能障碍及相关的肾小管间质纤维化是驱动肥胖相关CKD发生和进展的关键机制,但精确的交互机制尚不清楚。
- 针对肾纤维化的策略在人体研究中获益尚无定论。
- 实验数据提示运动、靶向炎症和氧化应激、降低尿酸以及靶向盐皮质激素受体信号和/或钠通道抑制可能改善肾小管间质纤维化并减缓肾病进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The global burden of kidney disease is increasing strikingly in parallel with increases in obesity and diabetes. Indeed, chronic kidney disease (CKD) and end-stage renal disease (ESRD) coupled with comorbidities such as obesity, diabetes, and hypertension cost the health care system hundreds of billions of dollars in the US alone. The progression to ESRD in patients with obesity and diabetes continues despite widespread use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) along with aggressive blood pressure and glycemic control in these high-risk populations. Thereby, it is increasingly important to better understand the underlying mechanisms involved in obesity-related CKD in order to develop new strategies that prevent or interrupt the progression of this costly disease. In this context, a key mechanism that drives development and progression of kidney disease in obesity is endothelial dysfunction and associated tubulointerstitial fibrosis. However, the precise interactive mechanisms in the development of aortic and kidney endothelial dysfunction and tubulointerstitial fibrosis remain unclear. Further, strategies specifically targeting kidney fibrosis have yielded inconclusive benefits in human studies. While clinical data support the benefits derived from inhibition of the RAAS, there is a tremendous amount of residual risk for the progression of kidney disease in individuals with obesity and diabetes. There is promising experimental data to suggest that exercise, targeting inflammation and oxidative stress, lowering uric acid, and targeting the mineralocorticoid receptor signaling and/or sodium channel inhibition could improve tubulointerstitial fibrosis and mitigate progression of kidney disease in persons with obesity and diabetes.
引用
- Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int. 2017. PMID: 28341271. doi:10.1016/j.kint.2016.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。